PMID- 30521587
OWN - NLM
STAT- MEDLINE
DCOM- 20190517
LR  - 20200309
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 12
DP  - 2018
TI  - A randomized controlled trial to evaluate performance of pigs raised in 
      antibiotic-free or conventional production systems following challenge with 
      porcine reproductive and respiratory syndrome virus.
PG  - e0208430
LID - 10.1371/journal.pone.0208430 [doi]
LID - e0208430
AB  - The trial objective was to compare the performance and animal health parameters 
      of pigs raised according to one of 3 antibiotic (AB) protocols: standard AB 
      medication consisting of mass treatment on days 4 and 21 and judicious AB therapy 
      given therapeutically thereafter as group medication in water and feed or by 
      individual injection (group T1, N = 702); modified AB medication identical to 
      group T1 but with mass treatment only on day 4 and without subsequent therapeutic 
      feed medication (group T2, N = 675); or an antibiotic-free (ABF) regimen (group 
      T3, N = 702). All pigs were vaccinated with a modified-live porcine reproductive 
      and respiratory syndrome virus (PRRSV) vaccine 3 days after weaning. Using a 
      seeder pig model to mimic endemic field infection dynamics, pigs were 
      contact-challenged with virulent PRRSV lineage 1 strain 174 four weeks after 
      vaccination. At finishing, average daily gain (ADG) and mean feed conversion 
      ratio (FCR) were significantly better (p </= 0.05) for the T1 and T2 groups 
      compared to the T3 group. There were no significant differences in post-weaning 
      ADG and FCR between the T1 and T2 groups. Mortality and removals significantly 
      favored (p </=0.05) the T1 and T2 groups (20.94% and 24.89%, respectively) versus 
      the T3 group (57.98%). Net revenue per pig was $105.43, $98.79, and $33.81 for 
      the T1, T2 and T3 groups, respectively. Under the conditions of this study, these 
      results indicate that in a PRRSV-endemic setting involving bacterial 
      co-infections, an ABF production strategy may leave pigs at considerable risk of 
      exposure to severe clinical disease and that judicious use of antibiotics can 
      significantly improve animal health.
FAU - Dee, Scott
AU  - Dee S
AUID- ORCID: 0000-0001-8691-3887
AD  - Pipestone Applied Research, Pipestone, Minnesota, United States of America.
FAU - Guzman, Jose Ezequiel
AU  - Guzman JE
AD  - Swine Technical Services, Zoetis, Parsippany, New Jersey, United States of 
      America.
FAU - Hanson, Dan
AU  - Hanson D
AD  - Pipestone Applied Research, Pipestone, Minnesota, United States of America.
FAU - Garbes, Noel
AU  - Garbes N
AD  - Swine Technical Services, Zoetis, Parsippany, New Jersey, United States of 
      America.
FAU - Morrison, Robert
AU  - Morrison R
AD  - College of Veterinary Medicine, University of Minnesota, St. Paul, Minnesota, 
      United States of America.
FAU - Amodie, Deborah
AU  - Amodie D
AD  - Outcomes Research, Zoetis, Parsippany, New Jersey, United States of America.
FAU - Galina Pantoja, Lucina
AU  - Galina Pantoja L
AUID- ORCID: 0000-0001-6240-7795
AD  - Swine Technical Services, Zoetis, Parsippany, New Jersey, United States of 
      America.
LA  - eng
PT  - Clinical Trial, Veterinary
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181206
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Vaccines, Attenuated)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Body Weight
MH  - Male
MH  - Mass Vaccination/*veterinary
MH  - Porcine Reproductive and Respiratory Syndrome/prevention & control
MH  - Porcine respiratory and reproductive syndrome virus/*immunology
MH  - Random Allocation
MH  - Swine/*growth & development/virology
MH  - Vaccination/*veterinary
MH  - Vaccines, Attenuated/administration & dosage
MH  - Weaning
PMC - PMC6283559
COIS- LGP, JEG, NG and DA are employed by and receive salary from Zoetis. SD and DH are 
      employed by Pipestone. There are no patents, products in development or marketed 
      products to declare. This does not alter our adherence to PLOS ONE policies on 
      sharing data and materials. The authors would like to confirm that we don't have 
      competing interest that alter our adherence to PLOS ONE policies on sharing data 
      and materials (as detailed online in our guide for authors 
      http://journals.plos.org/plosone/s/competing-interests).
EDAT- 2018/12/07 06:00
MHDA- 2019/05/18 06:00
PMCR- 2018/12/06
CRDT- 2018/12/07 06:00
PHST- 2018/04/14 00:00 [received]
PHST- 2018/11/15 00:00 [accepted]
PHST- 2018/12/07 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/05/18 06:00 [medline]
PHST- 2018/12/06 00:00 [pmc-release]
AID - PONE-D-18-10826 [pii]
AID - 10.1371/journal.pone.0208430 [doi]
PST - epublish
SO  - PLoS One. 2018 Dec 6;13(12):e0208430. doi: 10.1371/journal.pone.0208430. 
      eCollection 2018.